Core Insights - GIC Private Limited has increased its stake in Basilea Pharmaceutica AG by acquiring 1.7955 million shares at a price of HKD 5.4692 per share, totaling approximately HKD 9.8199 million [1] - Following this acquisition, GIC's total shareholding in Basilea has risen to approximately 105 million shares, representing a 7.11% ownership [1] - GIC's consistent investment in Basilea, accumulating over 16 million shares since October 13, indicates strong confidence in the company's long-term value [1] Company Actions - The CEO and key executives of Basilea have also shown confidence in the company by purchasing shares multiple times since the second half of this year [1] - These internal purchases reflect the management's belief in the company's ability to maintain stable operations and achieve sustained growth [1] Market Implications - The dual support from international long-term capital and internal management suggests that Basilea's future market performance and strategic positioning warrant ongoing attention [1]
GIC连续加码基石药业-B 持股比例升至7.11%